These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

66 related articles for article (PubMed ID: 8291840)

  • 1. [An interview with Sylviane Muller by P Youinou. What is going to happen tomorrow in the field of synthetic peptides of autoantigens?].
    Muller S
    Ann Med Interne (Paris); 1993; 144(5):319-22. PubMed ID: 8291840
    [No Abstract]   [Full Text] [Related]  

  • 2. Interview with Jean-Pierre Revillard. What is going to happen tomorrow as far as treatment of autoimmune disorders is concerned?
    Revillard JP
    Ann Med Interne (Paris); 1997; 148(1):11-4. PubMed ID: 9137693
    [No Abstract]   [Full Text] [Related]  

  • 3. Interview with Robert Schwartz. What is going to happen tomorrow in the field exploring the relationship between viruses and autoimmunity?. Interview by P. Youinou.
    Schwartz R
    Ann Med Interne (Paris); 1992; 143(6):419-20. PubMed ID: 1295397
    [No Abstract]   [Full Text] [Related]  

  • 4. [An interview with Jean-Michel Dayer: what is going to happen tomorrow in the field of cytokines?. Interview by P Youinou].
    Dayer JM
    Ann Med Interne (Paris); 1992; 143(7):445-7. PubMed ID: 1300865
    [No Abstract]   [Full Text] [Related]  

  • 5. Interview with Graham Hughes. What is going to happen tomorrow in the field of anti-phospholipid antibodies?. Interview by P. Youinou.
    Hughes G
    Ann Med Interne (Paris); 1992; 143(6):417-8. PubMed ID: 1295396
    [No Abstract]   [Full Text] [Related]  

  • 6. Interview with Ivan M. Roitt. What is going to happen tomorrow as far as glycosylation of IgG is concerned?. Interview by P. Youinou.
    Roitt IM
    Ann Med Interne (Paris); 1993; 144(6):389-91. PubMed ID: 8122821
    [No Abstract]   [Full Text] [Related]  

  • 7. [Interview with Dominique Charron. What is going to happen tomorrow in the understanding of the functioning of HLA molecules?. Interview by P. Youinou].
    Charron D
    Ann Med Interne (Paris); 1995; 146(1):25-8. PubMed ID: 7741390
    [No Abstract]   [Full Text] [Related]  

  • 8. Interview with Joachim Robert Kalden. What is going to happen tomorrow as far as DNA and anti-DNA antibodies are concerned?. Interview by P. Youinou.
    Kalden JR
    Ann Med Interne (Paris); 1993; 144(7):463-4. PubMed ID: 8141512
    [No Abstract]   [Full Text] [Related]  

  • 9. Interview with Joaquim Coll. What is going to happen tomorrow as far as secondary Sjögren's syndrome is concerned?. Interview by P. Youinou.
    Coll J
    Ann Med Interne (Paris); 1993; 144(4):257-9. PubMed ID: 8368718
    [No Abstract]   [Full Text] [Related]  

  • 10. [Interview with Pierre Godeau, President of the Société Nationale Française de Médecine Interne. What is going to happen tomorrow in internal medicine?. Interview by Pierre Youinou].
    Godeau P
    Ann Med Interne (Paris); 1994; 145(1):3-6. PubMed ID: 8192278
    [No Abstract]   [Full Text] [Related]  

  • 11. Interview with Peter Lydyard. What is going to happen tomorrow as far as heat-shock proteins are concerned?
    Lydyard P
    Ann Med Interne (Paris); 1993; 144(2):97-8. PubMed ID: 8333667
    [No Abstract]   [Full Text] [Related]  

  • 12. Antigenic mimicry, clonal selection and autoimmunity.
    Cohen IR
    J Autoimmun; 2001 May; 16(3):337-40. PubMed ID: 11334501
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antigen-specific tolerance strategies for the prevention and treatment of autoimmune disease.
    Miller SD; Turley DM; Podojil JR
    Nat Rev Immunol; 2007 Sep; 7(9):665-77. PubMed ID: 17690713
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Autoantigen microarrays for multiplex characterization of autoantibody responses.
    Robinson WH; DiGennaro C; Hueber W; Haab BB; Kamachi M; Dean EJ; Fournel S; Fong D; Genovese MC; de Vegvar HE; Skriner K; Hirschberg DL; Morris RI; Muller S; Pruijn GJ; van Venrooij WJ; Smolen JS; Brown PO; Steinman L; Utz PJ
    Nat Med; 2002 Mar; 8(3):295-301. PubMed ID: 11875502
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An immunoreactive peptide of the FSH involved in autoimmune infertility.
    Gobert B; Jolivet-Reynaud C; Dalbon P; Barbarino-Monnier P; Faure GC; Jolivet M; Béné MC
    Biochem Biophys Res Commun; 2001 Dec; 289(4):819-24. PubMed ID: 11735119
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Autoantigens: the critical partner in initiating and propagating systemic autoimmunity.
    Duan-Porter WD; Casciola-Rosen L; Rosen A
    Ann N Y Acad Sci; 2005 Dec; 1062():127-36. PubMed ID: 16461795
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunogenicity and immunopathogenicity of an autoimmune epitope are potentiated by increasing MHC binding through residue substitution.
    Kozhich AT; Caspi RR; Berzofsky JA; Gery I
    J Immunol; 1997 May; 158(9):4145-51. PubMed ID: 9126974
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Extended repertoire of permissible peptide ligands for HLA-B*2702.
    Raghavan M; Lebrón JA; Johnson JL; Bjorkman PJ
    Protein Sci; 1996 Oct; 5(10):2080-8. PubMed ID: 8897608
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Interview with Jean-François Borel. What is going to happen tomorrow in the field of cyclosporine?].
    Borel JF
    Ann Med Interne (Paris); 1995; 146(4):251-3. PubMed ID: 7653946
    [No Abstract]   [Full Text] [Related]  

  • 20. Interaction of histones with phospholipids--implications for the exposure of histones on apoptotic cells.
    Fürnrohr BG; Groer GJ; Sehnert B; Herrmann M; Voll RE
    Autoimmunity; 2007 Jun; 40(4):322-6. PubMed ID: 17516219
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.